Heart Failure Enhanced Pulmonary Vein Arrhythmogenesis and Dysregulated Sodium and Calcium Homeostasis with Increased Calcium Sparks

Institute of Clinical Medicine, National Yang-Ming University school of medicine, Taiwan.
Journal of Cardiovascular Electrophysiology (Impact Factor: 2.96). 12/2011; 22(12):1378-86. DOI: 10.1111/j.1540-8167.2011.02126.x
Source: PubMed


HF Enhanced PV Arrhythmogenesis. Introduction: Late sodium currents and intracellular Ca2+ (Ca2+i) dynamics play an important role in arrhythmogenesis of pulmonary vein (PV) and heart failure (HF). It is not clear whether HF enhances PV arrhythmogenesis through modulation of Ca2+ homeostasis and increased late sodium currents. The aim of this study was to investigate the sodium and calcium homeostasis in PV cardiomyocytes with HF.
Methods and Results: Whole-cell patch clamp was used to investigate the action potentials and ionic currents in isolated rabbit single PV cardiomyocytes with and without rapid pacing induced HF. The Ca2+i dynamics were evaluated through fluorescence and confocal microscopy. As compared to control PV cardiomyocytes (n = 18), HF PV cardiomyocytes (n = 13) had a higher incidence of delayed afterdepolarization (45% vs 13%, P < 0.05) and faster spontaneous activity (3.0 ± 0.2 vs 2.1 ± 0.2 Hz, P < 0.05). HF PV cardiomyocytes had increased late Na+ currents, Na+/Ca2+ exchanger currents, and transient inward currents, but had decreased Na+ currents or L-type calcium currents. HF PV cardiomyocytes with pacemaker activity had larger Ca2+i transients (R410/485, 0.18 ± 0.04 vs 0.11 ± 0.02, P < 0.05), and sarcoplasmic reticulum Ca2+ stores. Moreover, HF PV cardiomyocytes with pacemaker activity (n = 18) had higher incidence (95% vs 70%, P < 0.05), frequency (7.8 ± 3.1 vs 2.3 ± 1.2 spark/mm/s, P < 0.05), amplitude (F/F0, 3.2 ± 0.8 vs 1.9 ± 0.5, P < 0.05), and longer decay time (65 ± 3 vs 48 ± 4 ms, P < 0.05) of Ca2+ sparks than control PV cardiomyocytes with pacemaker activity (n = 18).
Conclusions: Dysregulated sodium and calcium homeostasis, and enhanced calcium sparks promote arrhythmogenesis of PV cardiomyocytes in HF, which may play an important role in the development of atrial fibrillation. (J Cardiovasc Electrophysiol, Vol. 22, pp. 1378-1386, December 2011)

40 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Obesity is an important risk factor for atrial fibrillation (AF) and heart failure (HF). The effects of epicardial fat on atrial electrophysiology were not clear. This study was to evaluate whether HF may modulate the effects of epicardial fat on atrial electrophysiology. METHODS: Conventional microelectrodes recording was used to record the action potential in left (LA) and right (RA) atria of healthy (control) rabbits before and after application of epicardial fat from control or HF (ventricular pacing of 360-400bpm for 4weeks) rabbits. Adipokine profiles were checked in epicardial fat of control and HF rabbits. RESULTS: The LA 90% of AP duration was prolonged by control epicardial fat (from 77±6 to 87±7ms, p<0.05, n=7), and by HF epicardial fat (from 78±3 to 98±4ms, p<0.001, n=9). However, control or HF epicardial fat did not change the AP morphology in RA. HF epicardial fat increased the contractility in LA (61±11 vs. 35±6mg, p=0.001), but not in RA. Control fat did not change the LA or RA contractility. Moreover, control and HF epicardial fat induced early and delayed afterdepolarizations in LA and RA, but only HF epicardial fat provoked spontaneous activity and burst firing in LA (n=3/9, 33.3% vs. n=0/7, 0%, n=0/9, 0%, p<0.05). Compared to control fat, HF epicardial fat, had lower resistin, C-reactive protein and serum amyloid A, but similar interluekin-6, leptin, monocyte chemotactic protein-1, adiponectin and adipsin. CONCLUSIONS: HF epicardial fat increases atrial arrhythmogenesis, which may contribute to the higher atrial arrhythmia in obesity.
    International journal of cardiology 05/2012; 167(5). DOI:10.1016/j.ijcard.2012.05.009 · 4.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ectopic foci originating from the pulmonary veins (PVs) have been suggested as the underlying cause for generating atrial arrhythmias that include atrial fibrillation (AF). Recent experimental findings indicate two types of PV cells: pacemaking and non-pacemaking. In this study, we have developed two mathematical models for human PV cardiomyocytes with and without pacemaking activities. The models were reconstructed by modifying an existing model of the human right atrium to incorporate extant experimental data on the electrical differences between the two cell types. Differences in their action potential (AP) profiles and automaticity were reproduced by the models, which can be attributed to the observed differences in the current densities of I(NCX), I(to), I(Na) and I(Ca-L), as well as the difference in the channel kinetics of I(Ca-L) and inclusion of the I(f) and I(Ca-T) currents in the pacemaking cells. The developed models provide a useful tool suitable for studying the substrates for generating AF.
    Conference proceedings: ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 08/2012; 2012:199-202. DOI:10.1109/EMBC.2012.6345905
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atrial fibrillation and heart failure are both associated with increased morbidity as well as mortality, and there is a complex interaction between the two conditions. The increasing prevalence and incidence rates of AF and CHF, as well as emerging novel but relatively expensive treatments and interventions, have compounded the significant public health impact at a global level. Ongoing investigative efforts continue to advance the knowledge of the complex interplay between these two conditions. This review critically assesses the current evidence in the field regarding prognostication metrics, drug therapy, and interventions for AF in CHF. We will summarize the important new findings published over the last year, with a focus on the latest advances that are of clinical relevance.
    Current Heart Failure Reports 08/2012; 9(4). DOI:10.1007/s11897-012-0108-6
Show more